Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01772719
Recruitment Status :
(Principal Investigator left institution-study not continued)
The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.
Condition or disease
Drug: Simvastatin and zoledronic acid
We hypothesize that the addition of simvastatin and zoledronic acid to bortezomib, thalidomide, melphalan or dexamethasone based regimens will decrease drug resistance when treating refractory multiple myeloma. We hypothesize that the addition of simvastatin and zoledronic acid will not increase the chemotherapy toxicity significantly and will be tolerable for patients. We believe simvastatin and zoledronic acid have antitumor properties and will contribute to reversal of resistance. Treatment will be significantly enhanced when these agents are combined
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
have a definitive diagnosis of Multiple Myeloma (using the International Myeloma Working Group Guidelines).
meet one of the following two requirements:
Have achieved minimal response (MR) or stable disease (SD) in current treatment regimen after a minimum of two cycles.
Have partial response but show no further improvement in paraprotein levels in the latest two measurements.
must have measurable active or symptomatic disease. Measurable disease may be paraprotein or free light chains in serum or urine, or the presence of bone marrow plasma cells, defined by one or more of the following criteria:
Presence of serum M-protein concentration > 1g/dL.
Urine M-protein excretion > 200mg in 24-hour urine collection.
Bone marrow plasma cell percentage ≥ 30% (if no detectable M-protein or FLC.)
Age > 18 years of age.
If female with reproductive capacity: on effective means of birth control during the entire duration of the treatment.
Patients must have recovered from acute toxicities resulting from therapy administered prior to entering this study to grade 1 or less (CTCAE 4) Alopecia may not be resolved.
Ability to understand and willingness to sign a written informed consent document.
Life expectancy of greater than 8 weeks.
ECOG performance status 0, 1, or 2 (Karnofsky > 60%; see Appendix A).
have adequate bone marrow function as defined below:
absolute neutrophil count > 500/ul
platelets > 30,000/ul
have adequate liver function as defined below:
total bilirubin < 2 times the upper limit of normal
AST(SGOT), ALT(SGPT) < 3 x upper limit of normal
have adequate renal function as defined by a creatinine clearance > 40 mL/min (measured or estimated by the Cockcroft-Gault formula).
have no signs of significant rhabdomyolysis determined by CPK levels with a CK < 5 times the upper limit of normal.
have not received any chemotherapy treatment for multiple myeloma prior to being enrolled in the study.
show progressive disease or are not tolerating current chemotherapy regimen.
were receiving simvastatin (dose > 40mg/day) while receiving current chemotherapy regimen for multiple myeloma.
failed or progressed on more than two chemotherapy regimens, including current treatment; prior to enrolling in this study.
receiving any other investigational agent(s).
Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ.
Pregnant women are ineligible, as treatment involves unforeseeable risks to the embryo or fetus. Female patients with reproductive capacity are required to use effective means of birth control during the entire duration of the treatment.
History of hypersensitivity reactions attributed to simvastatin or zoledronic acid.
receiving medications that may increase risk of rhabdomyolysis such as itraconazole, ketoconazole, erythromycin, cyclosporine, amiodarone, verapamil, clarithromycin, nefazodone, ranolazine, HIV protease inhibitors, gemfibrozil, posaconazole, danazol, amiodarone, diltiazem and amlodipine.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myopathy, untreated hypothyroidism, hereditary myopathy in the family history, unstable angina pectoris, liver disease not due to multiple myeloma, cardiac arrhythmia that is symptomatic or not rate controlled, active connective tissue disease, active autoimmune disease, or psychiatric illness/social situations that would limit compliance with study requirements.